Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study

References

1. ↵
   1. Dohner H,
   2. Weisdorf DJ,
   3. Bloomfield CD

   (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152.
2. ↵
   1. American Cancer Society

   (2018) What is acute myeloid leukemia (American Cancer Society, Atlanta).
3. ↵
   1. Ferlay J,
   2. Soerjomataram I,
   3. Ervik M,
   4. Dikshit R,
   5. Eser S,
   6. Mathers C,
   7. et al.

   (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide:IARC CancerBase No. 11 [Internet] (International Agency for Research on Cancer, Lyon (FR)).
4. ↵
   1. Saudi Cancer Registry

   (2017) Cancer Incidence Report in Saudi Arabia 2014-2017 (Saudi Cancer Registry, Riyadh (KSA)).
5. ↵
   1. World Health Organization

   (2017) AML classification biology and prognosis (World Health Organization, Geneva).
6. ↵
   1. Cancer and Leukemia Group B 84611,
   2. Farag SS,
   3. Archer KJ,
   4. Mrózek K,
   5. Ruppert AS,
   6. Carroll AJ,
   7. et al.

   (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:results from Cancer and Leukemia Group B 8461. Blood 108:63–73.
7. ↵
   1. Velloso ED,
   2. Motta CH,
   3. Furtado JB,
   4. Bacal NS,
   5. Silveira PA,
   6. Moyses CB,
   7. et al.

   (2011) Molecular and cytogenetic abnormalities in acute myeloid leukemia:and case studies. Einstein (Sao Paulo) 9:184–189.
8. ↵
   1. Gupta M,
   2. Mahapatra M,
   3. Saxena R

   (2019) Cytogenetics'impact on the prognosis of acute myeloid leukemia. J Lab Physicians 11:133.
9. ↵
   1. Wang ZY,
   2. Chen Z

   (2008) Acute promyelocytic leukemia:from highly fatal to highly curable. Blood 111:2505–2515.
10. ↵
    1. Ng C,
    2. Chng W

    (2017) Recent advances in acute promyelocytic leukaemia. F1000Res 6:1273.
11. ↵
    1. Alrajeh A,
    2. Abalkhail H,
    3. Khalil S

    (2017) Cytogenetics and molecular markers of acute myeloid leukemia from a tertiary care center in Saudi Arabia. Journal of Applied Hematolology 8:68–74.
12. ↵
    1. Manola KN,
    2. Panitsas F,
    3. Polychronopoulou S,
    4. Daraki A,
    5. Karakosta M,
    6. Stavropoulou C,
    7. et al.

    (2013) Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia:correlations with clinical characteristics and outcome. Cancer Genet 206:63–72.
13. ↵
    1. Byrd JC,
    2. Mrózek K,
    3. Dodge RK,
    4. Carroll AJ,
    5. Edwards CG,
    6. Arthur DC,
    7. et al.

    (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336.